A novel thyroid hormone receptor-β mutation that fails to bind nuclear receptor corepressor in a patient as an apparent cause of severe, predominantly pituitary resistance to thyroid hormone

Sharon Y. Wu, Ronald N. Cohen, Enver Simsek, Dursun A. Senses, Nese E. Yar, Helmut Grasberger, Janet Noel, Samuel Refetoff, Roy E Weiss

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Context: Resistance to thyroid hormone (RTH) is a dominantly inherited syndrome of variable tissue hyporesponsiveness to thyroid hormone (TH). Objective: We report a newborn who presented with severe RTH (Mkar) with serum TSH 1500 mU/liter and free T3 greater than 50 pM (normal 3.1-9.4) and free T4 25.3 pM (normal 12-22).Wehypothesized that the RTH was due to reduced ligand binding and/or abnormal interaction with nuclear cofactors. Design: These were prospective in vivo and in vitro studies. Setting: The study was conducted at a tertiary care university hospital. Patients: Patients included a newborn child and two other subjects with RTH. Intervention: The effect of various TH-lowering agents in the subject with RTH was studied. In vitro studies including EMSA and mammalian two-hybrid assay as well as in vitro transfection studies were conducted. Main Outcome Measures: Sequencing of theTHreceptor (TR)β and in vitro measurements of receptor-cofactor interaction were measured. Results: Sequencing of the TRβ demonstrated a de novo heterozygous mutation, 1590_1591insT, resulting in a frameshift producing a mutant TRβ(mutTR)- β with a 28-amino acid (aa) nonsense sequence and 2-amino acid carboxyl-terminal extension. The Mkar mutation was evaluated in comparison to three other TRβ frameshift mutations in the carboxyl terminus. EMSA demonstrated that the Mkar mutTRβ1 had impaired ability to recruit nuclear receptor corepressor but intact association with silencing mediator of retinoid and thyroid receptor (SMRT). Conclusion: Our data suggest that alterations in codons 436-453 in helix 11 result in significantly diminished association with nuclear receptor corepressor but not SMRT. This novel mutTRβ demonstrates nuclear corepressor specificity that results in severe predominantly pituitary RTH due to impaired release of SMRT.

Original languageEnglish (US)
Pages (from-to)1887-1895
Number of pages9
JournalJournal of Clinical Endocrinology and Metabolism
Volume91
Issue number5
DOIs
StatePublished - May 2006
Externally publishedYes

Fingerprint

Thyroid Hormone Resistance Syndrome
Thyroid Hormone Receptors
Co-Repressor Proteins
Thyroid Hormones
Mutation
Retinoids
Thyroid Gland
Newborn Infant
Two-Hybrid System Techniques
Frameshift Mutation
Association reactions
Tertiary Healthcare
Amino Acids
Codon
Transfection
Amino Acid Sequence
Outcome Assessment (Health Care)
Ligands
Assays
In Vitro Techniques

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

A novel thyroid hormone receptor-β mutation that fails to bind nuclear receptor corepressor in a patient as an apparent cause of severe, predominantly pituitary resistance to thyroid hormone. / Wu, Sharon Y.; Cohen, Ronald N.; Simsek, Enver; Senses, Dursun A.; Yar, Nese E.; Grasberger, Helmut; Noel, Janet; Refetoff, Samuel; Weiss, Roy E.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 91, No. 5, 05.2006, p. 1887-1895.

Research output: Contribution to journalArticle

Wu, Sharon Y. ; Cohen, Ronald N. ; Simsek, Enver ; Senses, Dursun A. ; Yar, Nese E. ; Grasberger, Helmut ; Noel, Janet ; Refetoff, Samuel ; Weiss, Roy E. / A novel thyroid hormone receptor-β mutation that fails to bind nuclear receptor corepressor in a patient as an apparent cause of severe, predominantly pituitary resistance to thyroid hormone. In: Journal of Clinical Endocrinology and Metabolism. 2006 ; Vol. 91, No. 5. pp. 1887-1895.
@article{2acfb3c1325748b5a327d544c67db013,
title = "A novel thyroid hormone receptor-β mutation that fails to bind nuclear receptor corepressor in a patient as an apparent cause of severe, predominantly pituitary resistance to thyroid hormone",
abstract = "Context: Resistance to thyroid hormone (RTH) is a dominantly inherited syndrome of variable tissue hyporesponsiveness to thyroid hormone (TH). Objective: We report a newborn who presented with severe RTH (Mkar) with serum TSH 1500 mU/liter and free T3 greater than 50 pM (normal 3.1-9.4) and free T4 25.3 pM (normal 12-22).Wehypothesized that the RTH was due to reduced ligand binding and/or abnormal interaction with nuclear cofactors. Design: These were prospective in vivo and in vitro studies. Setting: The study was conducted at a tertiary care university hospital. Patients: Patients included a newborn child and two other subjects with RTH. Intervention: The effect of various TH-lowering agents in the subject with RTH was studied. In vitro studies including EMSA and mammalian two-hybrid assay as well as in vitro transfection studies were conducted. Main Outcome Measures: Sequencing of theTHreceptor (TR)β and in vitro measurements of receptor-cofactor interaction were measured. Results: Sequencing of the TRβ demonstrated a de novo heterozygous mutation, 1590_1591insT, resulting in a frameshift producing a mutant TRβ(mutTR)- β with a 28-amino acid (aa) nonsense sequence and 2-amino acid carboxyl-terminal extension. The Mkar mutation was evaluated in comparison to three other TRβ frameshift mutations in the carboxyl terminus. EMSA demonstrated that the Mkar mutTRβ1 had impaired ability to recruit nuclear receptor corepressor but intact association with silencing mediator of retinoid and thyroid receptor (SMRT). Conclusion: Our data suggest that alterations in codons 436-453 in helix 11 result in significantly diminished association with nuclear receptor corepressor but not SMRT. This novel mutTRβ demonstrates nuclear corepressor specificity that results in severe predominantly pituitary RTH due to impaired release of SMRT.",
author = "Wu, {Sharon Y.} and Cohen, {Ronald N.} and Enver Simsek and Senses, {Dursun A.} and Yar, {Nese E.} and Helmut Grasberger and Janet Noel and Samuel Refetoff and Weiss, {Roy E}",
year = "2006",
month = "5",
doi = "10.1210/jc.2005-2428",
language = "English (US)",
volume = "91",
pages = "1887--1895",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "5",

}

TY - JOUR

T1 - A novel thyroid hormone receptor-β mutation that fails to bind nuclear receptor corepressor in a patient as an apparent cause of severe, predominantly pituitary resistance to thyroid hormone

AU - Wu, Sharon Y.

AU - Cohen, Ronald N.

AU - Simsek, Enver

AU - Senses, Dursun A.

AU - Yar, Nese E.

AU - Grasberger, Helmut

AU - Noel, Janet

AU - Refetoff, Samuel

AU - Weiss, Roy E

PY - 2006/5

Y1 - 2006/5

N2 - Context: Resistance to thyroid hormone (RTH) is a dominantly inherited syndrome of variable tissue hyporesponsiveness to thyroid hormone (TH). Objective: We report a newborn who presented with severe RTH (Mkar) with serum TSH 1500 mU/liter and free T3 greater than 50 pM (normal 3.1-9.4) and free T4 25.3 pM (normal 12-22).Wehypothesized that the RTH was due to reduced ligand binding and/or abnormal interaction with nuclear cofactors. Design: These were prospective in vivo and in vitro studies. Setting: The study was conducted at a tertiary care university hospital. Patients: Patients included a newborn child and two other subjects with RTH. Intervention: The effect of various TH-lowering agents in the subject with RTH was studied. In vitro studies including EMSA and mammalian two-hybrid assay as well as in vitro transfection studies were conducted. Main Outcome Measures: Sequencing of theTHreceptor (TR)β and in vitro measurements of receptor-cofactor interaction were measured. Results: Sequencing of the TRβ demonstrated a de novo heterozygous mutation, 1590_1591insT, resulting in a frameshift producing a mutant TRβ(mutTR)- β with a 28-amino acid (aa) nonsense sequence and 2-amino acid carboxyl-terminal extension. The Mkar mutation was evaluated in comparison to three other TRβ frameshift mutations in the carboxyl terminus. EMSA demonstrated that the Mkar mutTRβ1 had impaired ability to recruit nuclear receptor corepressor but intact association with silencing mediator of retinoid and thyroid receptor (SMRT). Conclusion: Our data suggest that alterations in codons 436-453 in helix 11 result in significantly diminished association with nuclear receptor corepressor but not SMRT. This novel mutTRβ demonstrates nuclear corepressor specificity that results in severe predominantly pituitary RTH due to impaired release of SMRT.

AB - Context: Resistance to thyroid hormone (RTH) is a dominantly inherited syndrome of variable tissue hyporesponsiveness to thyroid hormone (TH). Objective: We report a newborn who presented with severe RTH (Mkar) with serum TSH 1500 mU/liter and free T3 greater than 50 pM (normal 3.1-9.4) and free T4 25.3 pM (normal 12-22).Wehypothesized that the RTH was due to reduced ligand binding and/or abnormal interaction with nuclear cofactors. Design: These were prospective in vivo and in vitro studies. Setting: The study was conducted at a tertiary care university hospital. Patients: Patients included a newborn child and two other subjects with RTH. Intervention: The effect of various TH-lowering agents in the subject with RTH was studied. In vitro studies including EMSA and mammalian two-hybrid assay as well as in vitro transfection studies were conducted. Main Outcome Measures: Sequencing of theTHreceptor (TR)β and in vitro measurements of receptor-cofactor interaction were measured. Results: Sequencing of the TRβ demonstrated a de novo heterozygous mutation, 1590_1591insT, resulting in a frameshift producing a mutant TRβ(mutTR)- β with a 28-amino acid (aa) nonsense sequence and 2-amino acid carboxyl-terminal extension. The Mkar mutation was evaluated in comparison to three other TRβ frameshift mutations in the carboxyl terminus. EMSA demonstrated that the Mkar mutTRβ1 had impaired ability to recruit nuclear receptor corepressor but intact association with silencing mediator of retinoid and thyroid receptor (SMRT). Conclusion: Our data suggest that alterations in codons 436-453 in helix 11 result in significantly diminished association with nuclear receptor corepressor but not SMRT. This novel mutTRβ demonstrates nuclear corepressor specificity that results in severe predominantly pituitary RTH due to impaired release of SMRT.

UR - http://www.scopus.com/inward/record.url?scp=33646414780&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646414780&partnerID=8YFLogxK

U2 - 10.1210/jc.2005-2428

DO - 10.1210/jc.2005-2428

M3 - Article

VL - 91

SP - 1887

EP - 1895

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 5

ER -